Bank of New York Mellon’s Fate Therapeutics FATE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $30.7K | Sell |
11,381
-295,606
| -96% | -$547K | ﹤0.01% | 4254 |
|
|
2026
Q1 | $368K | Sell |
306,987
-610
| -0.2% | -$743 | ﹤0.01% | 3742 |
|
|
2025
Q4 | $302K | Sell |
307,597
-8,739
| -3% | -$10.5K | ﹤0.01% | 3853 |
|
|
2025
Q3 | $399K | Buy |
316,336
+25,684
| +9% | +$27.7K | ﹤0.01% | 3724 |
|
|
2025
Q2 | $326K | Sell |
290,652
-1,103
| -0.4% | -$1.28K | ﹤0.01% | 3752 |
|
|
2025
Q1 | $231K | Sell |
291,755
-1,251
| -0.4% | -$1.53K | ﹤0.01% | 3826 |
|
|
2024
Q4 | $483K | Sell |
293,006
-6,280
| -2% | -$15.8K | ﹤0.01% | 3547 |
|
|
2024
Q3 | $1.05M | Sell |
299,286
-74,846
| -20% | -$291K | ﹤0.01% | 3119 |
|
|
2024
Q2 | $1.23M | Buy |
374,132
+72,139
| +24% | +$316K | ﹤0.01% | 3076 |
|
|
2024
Q1 | $2.22M | Sell |
301,993
-19,959
| -6% | -$124K | ﹤0.01% | 2711 |
|
|
2023
Q4 | $1.2M | Buy |
321,952
+9,164
| +3% | +$21.6K | ﹤0.01% | 3092 |
|
|
2023
Q3 | $663K | Sell |
312,788
-10,852
| -3% | -$36K | ﹤0.01% | 3403 |
|
|
2023
Q2 | $1.54M | Sell |
323,640
-31,552
| -9% | -$174K | ﹤0.01% | 2973 |
|
|
2023
Q1 | $2.02M | Sell |
355,192
-7,882
| -2% | -$47.6K | ﹤0.01% | 2797 |
|
|
2022
Q4 | $3.66M | Sell |
363,074
-27,195
| -7% | -$511K | ﹤0.01% | 2516 |
|
|
2022
Q3 | $8.75M | Buy |
390,269
+39,739
| +11% | +$1.15M | ﹤0.01% | 1970 |
|
|
2022
Q2 | $8.69M | Sell |
350,530
-4,419
| -1% | -$122K | ﹤0.01% | 2024 |
|
|
2022
Q1 | $13.8M | Sell |
354,949
-3,446
| -1% | -$133K | ﹤0.01% | 1894 |
|
|
2021
Q4 | $21M | Buy |
358,395
+15,085
| +4% | +$855K | ﹤0.01% | 1701 |
|
|
2021
Q3 | $20.3M | Buy |
343,310
+15,842
| +5% | +$1.24M | ﹤0.01% | 1718 |
|
|
2021
Q2 | $28.4M | Buy |
327,468
+23,128
| +8% | +$1.86M | 0.01% | 1528 |
|
|
2021
Q1 | $25.1M | Sell |
304,340
-10,883
| -3% | -$1.04M | 0.01% | 1569 |
|
|
2020
Q4 | $28.7M | Sell |
315,223
-1,036
| -0.3% | -$64.3K | 0.01% | 1408 |
|
|
2020
Q3 | $12.6M | Buy |
316,259
+32,774
| +12% | +$1.14M | ﹤0.01% | 1723 |
|
|
2020
Q2 | $9.73M | Sell |
283,485
-16
| -0% | -$477 | ﹤0.01% | 1854 |
|
|
2020
Q1 | $6.3M | Buy |
283,501
+44,992
| +19% | +$1.14M | ﹤0.01% | 1957 |
|
|
2019
Q4 | $4.67M | Buy |
238,509
+19,993
| +9% | +$318K | ﹤0.01% | 2373 |
|
|
2019
Q3 | $3.39M | Sell |
218,516
-13,139
| -6% | -$252K | ﹤0.01% | 2468 |
|
|
2019
Q2 | $4.7M | Sell |
231,655
-19,232
| -8% | -$347K | ﹤0.01% | 2361 |
|
|
2019
Q1 | $4.41M | Buy |
250,887
+5,375
| +2% | +$84.8K | ﹤0.01% | 2395 |
|
|
2018
Q4 | $3.15M | Sell |
245,512
-21,263
| -8% | -$296K | ﹤0.01% | 2516 |
|
|
2018
Q3 | $4.34M | Sell |
266,775
-23,754
| -8% | -$281K | ﹤0.01% | 2473 |
|
|
2018
Q2 | $3.29M | Buy |
290,529
+13,839
| +5% | +$152K | ﹤0.01% | 2590 |
|
|
2018
Q1 | $2.7M | Buy |
276,690
+124,201
| +81% | +$1.19M | ﹤0.01% | 2655 |
|
|
2017
Q4 | $931K | Sell |
152,489
-448
| -0.3% | -$2K | ﹤0.01% | 3292 |
|
|
2017
Q3 | $606K | Sell |
152,937
-4,609
| -3% | -$15.7K | ﹤0.01% | 3486 |
|
|
2017
Q2 | $511K | Buy |
157,546
+98,036
| +165% | +$376K | ﹤0.01% | 3586 |
|
|
2017
Q1 | $271K | Buy |
59,510
+952
| +2% | +$3.48K | ﹤0.01% | 3782 |
|
|
2016
Q4 | $147K | Sell |
58,558
-2,572
| -4% | -$6.88K | ﹤0.01% | 3959 |
|
|
2016
Q3 | $191K | Sell |
61,130
-7,314
| -11% | -$17.7K | ﹤0.01% | 3903 |
|
|
2016
Q2 | $117K | Buy |
68,444
+4,941
| +8% | +$8.96K | ﹤0.01% | 4020 |
|
|
2016
Q1 | $114K | Buy |
63,503
+75
| +0.1% | +$154 | ﹤0.01% | 3936 |
|
|
2015
Q4 | $213K | Hold |
63,428
| – | – | ﹤0.01% | 3851 |
|
|
2015
Q3 | $338K | Buy |
63,428
+21,662
| +52% | +$148K | ﹤0.01% | 3730 |
|
|
2015
Q2 | $270K | Buy |
41,766
+3,323
| +9% | +$19.9K | ﹤0.01% | 3811 |
|
|
2015
Q1 | $188K | Hold |
38,443
| – | – | ﹤0.01% | 3906 |
|
|
2014
Q4 | $193K | Hold |
38,443
| – | – | ﹤0.01% | 3900 |
|
|
2014
Q3 | $196K | Hold |
38,443
| – | – | ﹤0.01% | 3901 |
|
|
2014
Q2 | $242K | Buy |
38,443
+43
| +0.1% | +$303 | ﹤0.01% | 3793 |
|
|
2014
Q1 | $374K | Buy |
+38,400
| New | +$297K | ﹤0.01% | 3667 |
|
Other funds holding FATE
JJ
PFM
GCP
YIH
Bank of New York Mellon's FATE Position: Q2 2026 in Review
Bank of New York Mellon reduced its Fate Therapeutics (FATE) stake by 96% in Q2 2026, selling an estimated $547K and leaving 11,381 shares worth $30.7K. The position accounts for ﹤0.01% of the portfolio, ranked #4254.
Bank of New York Mellon first reported a position in FATE in Q1 2014 and has held it in 50 quarters since. The position peaked at $28.7M in Q4 2020. 54 funds tracked by Wall St. Rank hold FATE as of Q2 2026.
- Bank of New York Mellon held 11,381 shares of Fate Therapeutics worth $30.7K as of Q2 2026.
- Bank of New York Mellon sold 295,606 Fate Therapeutics shares in Q2 2026, an estimated $547K.
- Fate Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #4254 holding.
- Bank of New York Mellon first reported a position in Fate Therapeutics in Q1 2014 and has held it in 50 quarters since.
- Bank of New York Mellon's Fate Therapeutics position peaked at $28.7M in Q4 2020.
- 54 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.